Stock-Based Compensation - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Stock-Based Compensation
Total stock-based compensation expense	$ 1,598	$ 1,351	$ 3,809	$ 2,886
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense
Stock-Based Compensation
Total stock-based compensation expense	1,074	1,005	2,493	2,151
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Stock-Based Compensation
Total stock-based compensation expense	$ 524	$ 346	$ 1,316	$ 735

Summary of Significant Accounting Policies	6 Months Ended
Jun. 30, 2026
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025 and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2026. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of June 30, 2026 and the results of its operations for the three and six months ended June 30, 2026 and 2025 and cash flows for the six months ended June 30, 2026 and 2025. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results for the year ending December 31, 2026 or for any future period. On March 13, 2026, the Company effected a reverse stock split of its common stock at a ratio of 1-for-14. The reverse stock split did not impact the number of authorized shares of common stock or preferred stock or the par value per share of the common stock or preferred stock. All share and per share amounts in these condensed consolidated financial statements and notes thereto have been adjusted retroactively to reflect the reverse stock split for all periods presented. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xilio Development, Inc. (“Xilio Development”), a Delaware corporation, and Xilio Securities Corporation, a Massachusetts security corporation. All intercompany accounts and transactions have been eliminated in consolidation. Significant Accounting Policies The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements are described in Note 2, “Summary of Significant Accounting Policies” of the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenue and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Factors that may affect estimates include expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Significant estimates of accounting reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, the valuation of the common stock warrant liabilities, the valuation of stock-based compensation, including stock options and restricted stock units, useful life of long-lived assets and income taxes. Actual results could differ from those estimates. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company holds all cash and cash equivalents at accredited financial institutions. Bank accounts in the United States are generally insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Substantially all of the Company’s cash and cash equivalents are FDIC insured, including funds held through an insured cash sweep program. The Company has not experienced any losses in its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Segments The Company has one operating and reportable segment, the consolidated Company operations, reflecting the integrated nature of its business focused on discovering and developing masked I-O therapies. The Company’s chief operating decision maker (“CODM”) is its chief executive officer. The CODM allocates resources and assesses performance on a consolidated basis, focused on the Company’s cash resources and an assessment of the probability of success of its ongoing research and development activities. Resource allocation decisions are informed by forecasted cash expenditures and actual expenses incurred to date. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the consolidated statements of operations and comprehensive loss, as the Company’s integrated operating model emphasizes shared resources and centralized decision-making. All of the Company’s collaboration and license revenue is generated in the United States and all of the Company’s long-lived assets are held in the United States. Recent Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on its consolidated financial statements and related disclosures.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2026

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company’s unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025 and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2026. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of June 30, 2026 and the results of its operations for the three and six months ended June 30, 2026 and 2025 and cash flows for the six months ended June 30, 2026 and 2025. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results for the year ending December 31, 2026 or for any future period.

On March 13, 2026, the Company effected a reverse stock split of its common stock at a ratio of 1-for-14. The reverse stock split did not impact the number of authorized shares of common stock or preferred stock or the par value per share of the common stock or preferred stock. All share and per share amounts in these condensed consolidated financial statements and notes thereto have been adjusted retroactively to reflect the reverse stock split for all periods presented.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xilio Development, Inc. (“Xilio Development”), a Delaware corporation, and Xilio Securities Corporation, a Massachusetts security corporation. All intercompany accounts and transactions have been eliminated in consolidation.

Significant Accounting Policies

The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements are described in Note 2, “Summary of Significant Accounting Policies” of the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenue and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Factors that may affect estimates include expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Significant estimates of accounting reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, the valuation of the common stock warrant liabilities, the valuation of stock-based compensation, including stock options and restricted stock units, useful life of long-lived assets and income taxes. Actual results could differ from those estimates.

Concentrations of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company holds all cash and cash equivalents at accredited financial institutions. Bank accounts in the United States are generally insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Substantially all of the Company’s cash and cash equivalents are FDIC insured, including funds held through an insured cash sweep program. The Company has not experienced any losses in its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Segments

The Company has one operating and reportable segment, the consolidated Company operations, reflecting the integrated nature of its business focused on discovering and developing masked I-O therapies. The Company’s chief operating decision maker (“CODM”) is its chief executive officer. The CODM allocates resources and assesses performance on a consolidated basis, focused on the Company’s cash resources and an assessment of the probability of success of its ongoing research and development activities. Resource allocation decisions are informed by forecasted cash expenditures and actual expenses incurred to date. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the consolidated statements of operations and comprehensive loss, as the Company’s integrated operating model emphasizes shared resources and centralized decision-making.

All of the Company’s collaboration and license revenue is generated in the United States and all of the Company’s long-lived assets are held in the United States.

Recent Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on its consolidated financial statements and related disclosures.

Description of Business and Liquidity	6 Months Ended
Jun. 30, 2026
Description of Business, Liquidity and Going Concern
Description of Business and Liquidity	1. Description of Business and Liquidity Xilio Therapeutics, Inc. (“Xilio” or the “Company”) is a clinical-stage biotechnology company dedicated to discovering and developing masked immuno-oncology (“I-O”) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company was incorporated in Delaware in June 2020, and its headquarters are located in Waltham, Massachusetts. Since its inception, the Company has devoted substantially all of its financial resources and efforts to research and development activities. As of June 30, 2026, the Company had an accumulated deficit of $434.7 million and has incurred significant operating losses, including net losses of $15.9 million and $29.1 million for the six months ended June 30, 2026 and 2025, respectively. The Company expects its operating losses and negative operating cash flows to continue for the foreseeable future as it continues to advance its product candidates through clinical trials, maintains the infrastructure necessary to support these activities and continues to incur costs associated with operating as a public company. As of June 30, 2026, the Company had cash and cash equivalents of $136.0 million. Based on its current operating plans, the Company anticipates that its existing cash and cash equivalents as of June 30, 2026 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of the issuance of these condensed consolidated financial statements. However, the Company has based its estimates on assumptions that may prove to be wrong. If actual results differ from the Company’s estimates, the Company could exhaust its available capital resources sooner than it anticipates, in which case, the Company would be required to seek additional capital sooner or curtail planned activities to reduce operating expenses, which may have an adverse impact on the Company’s ability to achieve its business objectives.

Description of Business and Liquidity

6 Months Ended

Jun. 30, 2026

Description of Business, Liquidity and Going Concern

Description of Business and Liquidity

1. Description of Business and Liquidity

Xilio Therapeutics, Inc. (“Xilio” or the “Company”) is a clinical-stage biotechnology company dedicated to discovering and developing masked immuno-oncology (“I-O”) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company was incorporated in Delaware in June 2020, and its headquarters are located in Waltham, Massachusetts.

Since its inception, the Company has devoted substantially all of its financial resources and efforts to research and development activities. As of June 30, 2026, the Company had an accumulated deficit of $434.7 million and has incurred significant operating losses, including net losses of $15.9 million and $29.1 million for the six months ended June 30, 2026 and 2025, respectively. The Company expects its operating losses and negative operating cash flows to continue for the foreseeable future as it continues to advance its product candidates through clinical trials, maintains the infrastructure necessary to support these activities and continues to incur costs associated with operating as a public company.

As of June 30, 2026, the Company had cash and cash equivalents of $136.0 million. Based on its current operating plans, the Company anticipates that its existing cash and cash equivalents as of June 30, 2026 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of the issuance of these condensed consolidated financial statements.

However, the Company has based its estimates on assumptions that may prove to be wrong. If actual results differ from the Company’s estimates, the Company could exhaust its available capital resources sooner than it anticipates, in which case, the Company would be required to seek additional capital sooner or curtail planned activities to reduce operating expenses, which may have an adverse impact on the Company’s ability to achieve its business objectives.

Stock-Based Compensation - Stock option activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) $ / shares shares
Options Outstanding
Outstanding at beginning of period (in shares)	2,785,102
Granted (in shares)	59,519
Exercised (in shares)	(151)
Forfeited (in shares)	(389,625)
Outstanding at end of period (in shares)	2,454,845	2,785,102
Exercisable at end of period (in shares)	799,572
Weighted Average Exercise Price
Outstanding (in dollars per share) \| $ / shares	$ 14.28	$ 14.4
Granted (in dollars per share) \| $ / shares	8.15
Exercised (in dollars per share) \| $ / shares	7.7
Forfeited (in dollars per share) \| $ / shares	14.18
Exercisable at end of period (in dollars per share) \| $ / shares	$ 19.39
Weighted Average Remaining Contractual Term (In years)
Outstanding (in years)	8 years 3 months 18 days	9 years 1 month 6 days
Exercisable at end of period (in years)	6 days 14 hours
Aggregate Intrinsic Value
Outstanding (in dollars) \| $	$ 129	$ 27
Exercisable (in dollars) \| $	$ 24

Commitments and Contingencies

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies

Commitments and Contingencies

7. Commitments and Contingencies

The Company has an operating lease for its headquarters and a finance lease for certain lab equipment. In August 2019, the Company entered into a facility lease agreement with a landlord providing funding for tenant improvements and occupancy of approximately 27,830 square feet of office and laboratory space (the “premises”) at 828 Winter Street, Waltham, Massachusetts. The initial term of the lease expires in March 2030, unless terminated earlier in accordance with the terms of the lease. The Company has an option to extend the lease for an additional term of five years at then-market rates. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement, and management of the leased premises, which it began paying simultaneous with the rent commencement date in March 2020. As of June 30, 2026 and December 31, 2025, the Company had a letter of credit for the benefit of its landlord in the amount of $1.8 million, collateralized by a money market account, which is recorded as restricted cash on the condensed consolidated balance sheets.

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2026

Net Loss Per Share

Schedule of antidilutive securities excluded from computation of diluted net loss per share


	Six Months Ended
	June 30,
	2026		2025
Unvested restricted stock units		12,824		23,866
Outstanding stock options		2,454,845		818,173
Common stock warrants		8,205,921		14,287,787
Unvested employee stock purchase plan shares		5,254		4,453
Total common stock equivalents		10,678,844		15,134,279

Fair Value Measurements - Changes in the fair market value of common stock warrant liabilities classified within the Level 3 fair value hierarchy (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($)
Fair Value Measurements
Beginning balance	$ 29,560
Change in fair value of common stock warrant liabilities	$ 640
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Other income, net
Ending balance	$ 30,200
Series A
Fair Value Measurements
Beginning balance	23,100
Change in fair value of common stock warrant liabilities	830
Ending balance	23,930
Series C
Fair Value Measurements
Beginning balance	6,460
Change in fair value of common stock warrant liabilities	(190)
Ending balance	$ 6,270

Stock-Based Compensation - Stock Incentive Plan (Details) - $ / shares	1 Months Ended			6 Months Ended
	Jun. 30, 2026	Nov. 30, 2025	Sep. 30, 2021	Jun. 30, 2026	Dec. 31, 2025
Stock-Based Compensation
Common stock reserved for issuance (in shares)	24,590,394			24,590,394	20,469,237
Percentage of cumulative increase in shares available for issuance	5.00%			5.00%
Additional common stock reserved under the plan (in shares)	250,000
Stock options granted				59,519
Exercise price				$ 8.15
2021 Plan
Stock-Based Compensation
Common stock reserved for issuance (in shares)			469,929
Annual increase in number of shares reserved for issuance (as a percent)			5.00%
Shares available for future issuance (in shares)	354,198			354,198
2025 Plan
Stock-Based Compensation
Shares available for future issuance (in shares)	324,098			324,098
2025 Plan \| Employee Stock Option Member
Stock-Based Compensation
Stock options granted		2,285,592
Total shares per tranche		571,398
2025 Plan \| Employee Stock Option Member \| Tranche 1
Stock-Based Compensation
Vesting description				The first tranche of stock options vests in equal monthly installments over a period of three years, subject to the employee continuing to provide services to the Company on each vesting date.
Vesting period				3 years
2025 Plan \| Employee Stock Option Member \| Tranche 2
Stock-Based Compensation
Vesting description				The second tranche of stock options ("Tranche 2 Stock Options") will become eligible to vest based on the portion of such stock options that equals the percentage of the Series A warrants that are exercised by December 31 of each of 2025, 2026, 2027, 2028, and 2029 and on June 30, 2030 (each, a “measurement date”). Any Tranche 2 Stock Options will vest in three equal installments with one-third vesting on the applicable measurement date and the remaining two-thirds vesting in equal annual installments on each of the subsequent two anniversaries thereafter.
2025 Plan \| Employee Stock Option Member \| Tranche 3
Stock-Based Compensation
Vesting description				The third tranche of stock options ("Tranche 3 Stock Options") became eligible to vest based on the portion of such stock options that equaled the percentage of Series B warrants that were exercised by December 31, 2025. The Tranche 3 Stock Options vest in three equal installments with one-third vesting on December 31, 2025 and the remaining two-thirds vesting in equal annual installments on each of the subsequent two anniversaries thereafter.
2025 Plan \| Employee Stock Option Member \| Tranche 4
Stock-Based Compensation
Vesting description				The fourth tranche of stock options ("Tranche 4 Stock Options") will become eligible to vest based on the portion of such stock options that equal the percentage of the Series C warrants that are exercised or are cancelled due to the Company’s receipt of non-dilutive capital by December 31, 2026. Any Tranche 4 Stock Options that become eligible for vesting will vest in three equal installments with one-third vesting on December 31, 2026 and the remaining two-thirds vesting in equal annual installments on each of the subsequent two anniversaries thereafter.

Collaboration, License and Option Agreements - Summary of Contract Assets and Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($)
Deferred revenue
Deferred revenue as of beginning of period	$ 60,658
Additions	6,000
Collaboration and license revenue recognized	(31,340)
Deferred revenue as of end of period	35,318
Collaboration and Stock Purchase Agreement \| AbbVie
Deferred revenue
Deferred revenue as of beginning of period	34,007
Additions	6,000
Collaboration and license revenue recognized	(20,726)
Deferred revenue as of end of period	19,281
License and Stock Purchase Agreement \| Gilead
Deferred revenue
Deferred revenue as of beginning of period	26,651
Collaboration and license revenue recognized	(10,614)
Deferred revenue as of end of period	$ 16,037

Preferred Stock and Common Stock - Private Placement (Details)	3 Months Ended
	Jun. 30, 2026 shares
Preferred stock and Common stock
Common stock issued (in shares)	592,300

Commitments and Contingencies (Details) $ in Millions	1 Months Ended
Commitments and Contingencies (Details) $ in Millions	Aug. 31, 2019 ft²	Jun. 30, 2026 USD ($)	Dec. 31, 2025 USD ($)
Leases
Area leased (in square feet) \| ft²	27,830
Option to extend	true
Term of option to extend	5 years
Landlord
Leases
Letter of credit \| $		$ 1.8	$ 1.8

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Accrued Expenses
External research and development	$ 3,225	$ 3,767
Personnel-related	3,620	5,733
Professional and consulting fees	915	2,156
Other	94	83
Total accrued expenses	$ 7,854	$ 11,739

Preferred Stock and Common Stock - Sales Agreement and "At-The-Market" Facility (Details) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2025	Jun. 30, 2026	May 31, 2026
Preferred stock and Common stock
Common stock issued (in shares)		592,300
At-The-Market Offering, Leerink Sales Agreement
Preferred stock and Common stock
Gross proceeds from offerings		$ 4,600,000
Maximum amount of shares available	$ 50,000,000
Maximum stock offering, issuance and sale amount			$ 14,500,000
At-The-Market Offering, Leerink Sales Agreement \| Weighted average
Preferred stock and Common stock
Purchase price (in dollars per share)		$ 7.76

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - shares		1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jan. 01, 2026	Jun. 30, 2026	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2021	Dec. 31, 2025
Stock-Based Compensation
Common stock reserved for issuance (in shares)		24,590,394	24,590,394			20,469,237
Additional common stock reserved under the plan (in shares)		250,000
2021 ESPP
Stock-Based Compensation
Common stock reserved for issuance (in shares)		136,294	136,294		20,859	89,603
Annual increase in number of shares reserved for issuance (as a percent)					1.00%
Additional common stock reserved under the plan (in shares)	41,718
Shares issued under plan (in shares)			4,973	3,240
Shares available for future issuance (in shares)		136,294	136,294
2021 ESPP \| Maximum
Stock-Based Compensation
Annual increase in number of shares reserved and available for issuance (in shares)					41,718

Fair Value Measurements - Measurement Inputs of Common Stock Warrant Liabilities (Details)	Jun. 30, 2026 yr	Dec. 31, 2025 yr
Closing price of common stock
Fair Value Measurements
Measurement input	9.58	8.96
Warrant exercise price
Fair Value Measurements
Measurement input	10.5	10.5
Expected volatility
Fair Value Measurements
Measurement input	70	70
Risk free interest rate
Fair Value Measurements
Measurement input	4.09	3.62
Minimum \| Expected term (in years)
Fair Value Measurements
Measurement input	0.42	0.92
Maximum \| Expected term (in years)
Fair Value Measurements
Measurement input	3.93	4.43

Preferred Stock and Common Stock - Follow-On Offering (Details)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2026 USD ($) $ / shares shares	Jun. 30, 2026 USD ($) Item $ / shares shares	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) Item $ / shares shares	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) shares
Preferred stock and Common stock
Payments of stock issuance costs \| $				$ 1,550,000
Warrants and Rights Outstanding \| $		$ 30,200,000		30,200,000		$ 29,560,000
Other income, net \| $		$ 1,058,000	$ (1,428,000)	2,341,000	$ (842,000)
June 2025 Follow-On Offering
Preferred stock and Common stock
Gross proceeds from offerings \| $				50,000,000
Net proceeds from offerings \| $				47,000,000
Payments of stock issuance costs \| $				$ 3,000,000
Combined offering price per share \| $ / shares		$ 10.4986		$ 10.4986
Ownership limitation percentage		4.99%		4.99%
Effective period for change in ownership				61 days
Other income, net \| $		$ (3,900,000)		$ (600,000)
Maximum \| June 2025 Follow-On Offering
Preferred stock and Common stock
Ownership limitation percentage		19.99%		19.99%
Other income, net \| $			$ (100,000)		$ (100,000)
Prefunded warrants \| February 2026 Follow-On Offering
Preferred stock and Common stock
Net proceeds from offerings \| $	$ 37,300,000
Class of warrant or right number of securities called by warrants or rights	5,341,404
Exercise price, warrants (in dollars per share) \| $ / shares	$ 0.0014
Class of warrant or right number of securities called by each warrant or right	1
Purchase price of warrant \| $ / shares	$ 7.4886
Prefunded warrants \| June 2025 Follow-On Offering
Preferred stock and Common stock
Gross proceeds from offerings \| $				$ 11,500,000
Class of warrant or right number of securities called by warrants or rights		4,762,533		4,762,533		2,434,973
Number of units \| Item		1		1
Exercise price, warrants (in dollars per share) \| $ / shares		$ 0.0014		$ 0.0014
Prefunded warrants
Preferred stock and Common stock
Warrants exercised (in shares)				1,260,041
Warrants outstanding (in shares)		13,107,620		13,107,620
Prefunded warrants \| February 2026 Follow-On Offering
Preferred stock and Common stock
Debt Conversion, Converted Instrument, Warrants or Options Issued		200,298
Warrants and Rights Outstanding \| $		$ 5,141,106		$ 5,141,106
Prefunded warrants \| June 2025 Follow-On Offering
Preferred stock and Common stock
Warrants exercised (in shares)				0		524,033
Warrants outstanding (in shares)						4,238,500
Series A Warrants \| June 2025 Follow-On Offering
Preferred stock and Common stock
Gross proceeds from offerings \| $				$ 26,800,000
Class of warrant or right number of securities called by warrants or rights		4,762,533		4,762,533
Number of units \| Item		1		1
Exercise price, warrants (in dollars per share) \| $ / shares		$ 10.5		$ 10.5
Warrants exercised (in shares)				0
Warrants outstanding (in shares)		4,762,533		4,762,533
Warrants exercisable date				Dec. 01, 2025
Series B Warrants \| June 2025 Follow-On Offering
Preferred stock and Common stock
Gross proceeds from offerings \| $				$ 6,600,000
Class of warrant or right number of securities called by warrants or rights		4,762,533		4,762,533
Number of units \| Item		1		1
Proceeds from warrant gross \| $						$ 34,300,000
Warrants exercised (in shares)				0		3,443,388
Warrants exercisable date				Nov. 01, 2025
Warrants not exercised and expired						1,319,145
Series C Warrants
Preferred stock and Common stock
Warrants cancellation ratio				1.33
Series C Warrants \| June 2025 Follow-On Offering
Preferred stock and Common stock
Gross proceeds from offerings \| $				$ 5,100,000
Class of warrant or right number of securities called by warrants or rights		4,762,533		4,762,533
Number of units \| Item		1		1
Exercise price, warrants (in dollars per share) \| $ / shares		$ 10.5		$ 10.5
Purchase price per share \| $ / shares		$ 21		21
Warrants cancellation price per share \| $ / shares				$ 14
Warrants exercised (in shares)				0
Warrants outstanding (in shares)		3,443,388		3,443,388		3,443,388
Warrants expired						1,319,145
Series C Warrants \| Maximum \| June 2025 Follow-On Offering
Preferred stock and Common stock
Proceeds from warrant gross \| $						$ 36,200,000
Common Stock \| June 2025 Follow-On Offering
Preferred stock and Common stock
Class of warrant or right number of securities called by warrants or rights						1,008,415

Stock-Based Compensation - Stock Option Repricing (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2026	Dec. 31, 2025	Nov. 21, 2025
Stock-Based Compensation
Exercise price	$ 14.28	$ 14.4
Total number of shares of common stock	2,454,845	2,785,102
Stock Option Repricing
Stock-Based Compensation
Total number of shares of common stock			354,200
Total amount of the incremental compensation expense	$ 0.6
Stock Option Repricing \| All Other Employees
Stock-Based Compensation
Exercise price			$ 14
Stock Option Repricing \| Minimum \| Executive Team
Stock-Based Compensation
Exercise price			$ 21

Subsequent Events (Details) - shares	Jun. 30, 2026	Dec. 31, 2025
Subsequent Event [Line Items]
Common stock reserved for issuance (in shares)	24,590,394	20,469,237

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2026
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Securities Act File Number	001-40925
Entity Registrant Name	Xilio Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1623397
Entity Address, Address Line One	828 Winter Street
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	857
Local Phone Number	524-2466
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	XLO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001840233
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026

Stock-Based Compensation - Restricted Stock Units (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2024 Item shares	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2025 USD ($)
Weighted Average Grant Date Fair Value
Stock-based compensation expense \| $		$ 1,598	$ 1,351	$ 3,809	$ 2,886
Restricted stock units
Stock-Based Compensation
Number of equal annual installments in which units vest \| Item	4
Equity Based Compensation
Unvested awards at beginning of period (in shares)				23,866
Granted (in shares)	34,389
Vested (in shares)				(7,952)
Forfeited				3,090
Unvested awards at end of period (in shares)		12,824		12,824
Weighted Average Grant Date Fair Value
Unvested awards at beginning of period (in dollars per share) \| $ / shares				$ 7.7
Vested (in dollars per share) \| $ / shares				7.7
Forfeited (in dollars per share) \| $ / shares				7.7
Unvested awards at end of period (in dollars per share) \| $ / shares		$ 7.7		$ 7.7
Unrecognized stock-based compensation expense \| $		$ 100		$ 100
Weighted-average period for unrecognized compensation expense to be recognized				1 year 6 months
Restricted stock units \| Maximum
Weighted Average Grant Date Fair Value
Stock-based compensation expense \| $				$ 100	$ 100

Preferred Stock and Common Stock - Shares Reserved for Future Issuance (Details) - shares	Jun. 30, 2026	Dec. 31, 2025	Dec. 31, 2021
Shares for future issuance
Shares reserved for future issuance (in shares)	24,590,394	20,469,237
Stock options and unvested restricted stock units
Shares for future issuance
Shares reserved for future issuance (in shares)	3,140,559	2,963,086
Employee stock purchase plan
Shares for future issuance
Shares reserved for future issuance (in shares)	136,294	89,603	20,859
Common stock in process of settlement at period end
Shares for future issuance
Shares reserved for future issuance (in shares)		708,215
Common stock warrants
Shares for future issuance
Shares reserved for future issuance (in shares)	8,205,921	8,206,109
Prefunded warrants
Shares for future issuance
Shares reserved for future issuance (in shares)	13,107,620	8,502,224

Stock-Based Compensation - 2022 Inducement Plan (Details) - shares	1 Months Ended
	Jun. 30, 2026	Jan. 31, 2026	Nov. 30, 2025	Nov. 30, 2024	Dec. 31, 2025	Dec. 31, 2022
Stock-Based Compensation
Common stock reserved for issuance (in shares)	24,590,394				20,469,237
Additional common stock reserved under the plan (in shares)	250,000
2022 Inducement Plan
Stock-Based Compensation
Common stock reserved for issuance (in shares)						19,642
Shares available for future issuance (in shares)	318,692
Additional common stock reserved under the plan (in shares)		32,485	35,714	35,714

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 136,040	$ 137,531
Collaboration and license agreement receivable	6,000	5,000
Prepaid expenses and other current assets	3,428	2,496
Total current assets	145,468	145,027
Restricted cash	1,819	1,807
Property and equipment, net	3,359	3,892
Operating lease right-of-use asset	3,608	3,959
Total assets	154,254	154,685
Current liabilities
Accounts payable	2,315	3,168
Accrued expenses	7,854	11,739
Deferred revenue, current portion	22,603	40,023
Operating lease liability, current portion	1,426	1,343
Total current liabilities	34,198	56,273
Deferred revenue, net of current portion	12,715	20,635
Operating lease liability, net of current portion	4,877	5,611
Common stock warrant liabilities	30,200	29,560
Liabilities to issue common stock		7,333
Total liabilities	81,990	119,412
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred stock, $0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.0001 par value; 600,000,000 shares authorized; 6,580,149 shares issued and outstanding at June 30, 2026; 4,530,641 shares issued and outstanding at December 31, 2025	1	0
Additional paid-in capital	506,954	454,062
Accumulated deficit	(434,691)	(418,789)
Total stockholders' equity	72,264	35,273
Total liabilities and stockholders' equity	$ 154,254	$ 154,685

Preferred Stock and Common Stock - Authorized (Details) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Preferred Stock and Common Stock
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	600,000,000	600,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

Collaboration, License and Option Agreements - Gilead Sciences, Inc. (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($) Item $ / shares shares	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)
Agreements
Revenue		$ 18,692	$ 8,084	$ 31,340	$ 11,014
Revenue from Contract with Customer, Product and Service		Collaboration And License Member	Collaboration And License Member	Collaboration And License Member	Collaboration And License Member
Deferred revenue		$ 35,318		$ 35,318		$ 60,658
Deferred revenue, current portion		22,603		22,603		40,023
License and Stock Purchase Agreement \| Gilead Sciences, Inc.
Agreements
Maximum additional contingent payments receivable, Transition fee	$ 75,000			75,000
Gross proceeds from issuance of private placement	$ 25,000			25,000
Development milestone payment received from Gilead				17,500
Number of private placements \| Item	3
Common stock and prefunded warrants purchased (in shares) \| shares	650,387
Maximum beneficial ownership (as a percent)	19.90%
Upfront payment				72,500
Upfront payment, cash				30,000
Maximum additional contingent payments receivable				575,000
Maximum additional contingent payments receivable, Milestones				500,000
Maximum additional contingent payments receivable, Near-term development milestones						17,500
Fair market value of common stock issued (in dollars)	$ 4,400
Premium of common stock issued (in dollars)	$ 9,100
Number of promises \| Item	2
Transaction price	$ 39,100
Transaction price, Cash payment	30,000
Transaction price, Premium on sale of stock	$ 9,100
Revenue		6,000	$ 3,300	10,600	$ 5,500
Deferred revenue		16,037		16,037		$ 26,651
Deferred revenue, current portion		$ 13,200		$ 13,200
License and Stock Purchase Agreement \| Gilead Sciences, Inc. \| Prefunded warrants
Agreements
Number of common stock into which the class of warrant or right purchased may be converted \| shares	712,514
Exercise price, warrants (in dollars per share) \| $ / shares	$ 0.0014

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (15,902)	$ (29,109)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	675	878
Stock-based compensation expense	3,809	2,886
Change in fair value of common stock warrant liabilities	640	50
Issuance costs allocated to common stock warrant liabilities		2,284
Changes in operating assets and liabilities:
Collaboration and license agreement receivable	(1,000)
Prepaid and other assets	(581)	3,080
Accounts payable	(419)	1,522
Accrued expenses and other liabilities	(2,987)	(5,219)
Deferred revenue	(25,340)	38,129
Net cash (used in) provided by operating activities	(41,105)	14,501
Cash flows from investing activities:
Purchases of property and equipment	(575)	(423)
Net cash used in investing activities	(575)	(423)
Cash flows from financing activities:
Proceeds from issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs	37,256
Proceeds from issuance of prefunded warrants and common stock warrants in connection with a follow-on offering, net of issuance costs		47,318
Proceeds from issuance of common stock under employee stock purchase plan	36	40
Proceeds from exercise of stock options	1	9
Payments of issuance costs included in accounts payable or accrued expenses at prior year end	(1,550)
Net cash provided by financing activities	40,201	52,194
(Decrease) increase in cash, cash equivalents and restricted cash	(1,479)	66,272
Cash, cash equivalents and restricted cash, beginning of period	139,338	57,073
Cash, cash equivalents and restricted cash, end of period	137,859	123,345
Supplemental disclosure of non-cash activities:
Capital expenditures included in accounts payable or accrued expenses	10	284
Settlement Of Liabilities To Issue Common Stock By Issuing Common Stock	7,332
Reconciliation to amounts within the consolidated balance sheets:
Cash and cash equivalents	136,040	121,551
Restricted cash	1,819	1,794
Cash, cash equivalents and restricted cash, end of period	137,859	123,345
AbbVie Stock Purchase Agreement
Cash flows from financing activities:
Proceeds from issuance of common stock		2,810
At-The-Market Offerings
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 4,458	$ 2,017

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	6,580,149	4,530,641
Common stock, shares outstanding	6,580,149	4,530,641

Fair Value Measurements - Liabilities at fair value on a recurring basis (Details) - Recurring basis - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Fair Value Measurements
Total financial liabilities	$ 30,200	$ 29,560
Series A warrant to purchase common stock
Fair Value Measurements
Total financial liabilities	23,930	23,100
Series C warrant to purchase common stock
Fair Value Measurements
Total financial liabilities	6,270	6,460
Level 3
Fair Value Measurements
Total financial liabilities	30,200	29,560
Level 3 \| Series A warrant to purchase common stock
Fair Value Measurements
Total financial liabilities	23,930	23,100
Level 3 \| Series C warrant to purchase common stock
Fair Value Measurements
Total financial liabilities	$ 6,270	$ 6,460

Summary of Significant Accounting Policies - Segment Information (Details)	6 Months Ended
	Jun. 30, 2026 Segment
Summary of Significant Accounting Policies
Number of operating segments	1
Number of reportable segments	1

Basis of Presentation

Principles of Consolidation

Significant Accounting Policies

1. Description of Business and Liquidity

7. Commitments and Contingencies

3. Fair Value Measurements

10. Net Loss Per Share

9. Stock-Based Compensation

Equity Incentive Plans

2022 Inducement Plan

Stock Options

Restricted Stock Units

5. Accrued Expenses

8. Preferred Stock and Common Stock

Undesignated Preferred Stock

Common Stock

6. Collaboration, License and Option Agreements

Collaboration, License and Option Agreement with AbbVie

License Agreement with Gilead Sciences, Inc.

Clinical Trial Collaboration with F. Hoffmann-La Roche Ltd

4. Property and Equipment, Net

Basis of Presentation

Principles of Consolidation

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	AbbVie Stock Purchase Agreement	At-The-Market Offerings	Follow-on offering	Common Stock	Common Stock AbbVie Stock Purchase Agreement	Common Stock At-The-Market Offerings	Additional Paid-in Capital	Additional Paid-in Capital AbbVie Stock Purchase Agreement	Additional Paid-in Capital At-The-Market Offerings	Additional Paid-in Capital Follow-on offering	Additional Paid-in Capital follow-on public offering	Accumulated Deficit
Beginning balance at Dec. 31, 2024	$ 17,598							$ 401,351					$ (383,753)
Beginning balance (in shares) at Dec. 31, 2024					3,268,299
Stockholders' Deficit
Issuance of common stock, net of issuance costs (in shares)						310,559	110,747
Issuance of common stock, net of issuance costs	2,017	$ 2,810							$ 2,810	$ 2,017
Issuance of common stock and prefunded warrants, net of issuance costs				$ 10,818							$ 10,818
Issuance of common stock under employee stock purchase plan	40							40
Issuance of common stock under employee stock purchase plan (in shares)					3,240
Vesting of restricted common stock (in shares)					7,952
Exercise of stock options	9							9
Exercise of stock options (in shares)					1,155
Stock-based compensation expense	2,886							2,886
Net loss	(29,109)												(29,109)
Ending balance at Jun. 30, 2025	7,069							419,931					(412,862)
Ending balance (in shares) at Jun. 30, 2025					3,701,952
Beginning balance at Mar. 31, 2025	10,700							407,718					(397,018)
Beginning balance (in shares) at Mar. 31, 2025					3,698,205
Stockholders' Deficit
Issuance of common stock and prefunded warrants, net of issuance costs	10,818											$ 10,818
Issuance of common stock under employee stock purchase plan	40							40
Issuance of common stock under employee stock purchase plan (in shares)					3,240
Exercise of stock options	4							4
Exercise of stock options (in shares)					507
Stock-based compensation expense	1,351							1,351
Net loss	(15,844)												(15,844)
Ending balance at Jun. 30, 2025	7,069							419,931					(412,862)
Ending balance (in shares) at Jun. 30, 2025					3,701,952
Beginning balance at Dec. 31, 2025	35,273							454,062					(418,789)
Beginning balance (in shares) at Dec. 31, 2025					4,530,641
Stockholders' Deficit
Issuance of common stock, net of issuance costs (in shares)							592,300
Issuance of common stock, net of issuance costs	4,458									4,458
Issuance of common stock and prefunded warrants, net of issuance costs				$ 37,256							$ 37,256
Issuance of common stock and prefunded warrants, net of issuance costs (in shares)					735,909
Issuance of common stock under employee stock purchase plan	36							36
Issuance of common stock under employee stock purchase plan (in shares)					4,973
Issuance of common stock to settle the liabilities to issue common stock	7,333				$ 1			7,332
Issuance of common stock to settle liabilities to issue common stock (in shares)					708,223
Issuance of common stock in connection with the exercise of prefunded warrants (in shares)					735,909
Vesting of restricted common stock (in shares)					7,952
Exercise of stock options	$ 1							1
Exercise of stock options (in shares)	151				151
Stock-based compensation expense	$ 3,809							3,809
Net loss	(15,902)												(15,902)
Ending balance at Jun. 30, 2026	72,264				$ 1			506,954					(434,691)
Ending balance (in shares) at Jun. 30, 2026					6,580,149
Beginning balance at Mar. 31, 2026	$ 72,545				$ 1			500,862					(428,318)
Beginning balance (in shares) at Mar. 31, 2026					5,782,536
Stockholders' Deficit
Issuance of common stock, net of issuance costs (in shares)	592,300						592,300
Issuance of common stock and prefunded warrants, net of issuance costs			$ 4,458							$ 4,458
Issuance of common stock and prefunded warrants, net of issuance costs (in shares)					200,298
Issuance of common stock under employee stock purchase plan	$ 36							36
Issuance of common stock under employee stock purchase plan (in shares)					4,973
Issuance of common stock in connection with the exercise of prefunded warrants (in shares)					200,298
Exercise of stock options (in shares)					42
Stock-based compensation expense	1,598							1,598
Net loss	(6,373)												(6,373)
Ending balance at Jun. 30, 2026	$ 72,264				$ 1			$ 506,954					$ (434,691)
Ending balance (in shares) at Jun. 30, 2026					6,580,149

Collaboration, License and Option Agreements - Abbvie (Details) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 01, 2025 USD ($) shares	Jun. 30, 2026 USD ($) shares	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)	Feb. 28, 2025 USD ($) Program $ / shares
Agreements
Common stock issued and sold (in shares) \| shares		592,300
Revenue		$ 18,692	$ 8,084	$ 31,340	$ 11,014
Revenue from Contract with Customer, Product and Service		Collaboration And License Member	Collaboration And License Member	Collaboration And License Member	Collaboration And License Member
Deferred revenue		$ 35,318		$ 35,318		$ 60,658
Deferred revenue, current portion		22,603		22,603		40,023
AbbVie Stock Purchase Agreement
Agreements
Common stock issued and sold (in shares) \| shares	310,559
Purchase price (in dollars per share) \| $ / shares							$ 32.2
Development milestone related payment		6,000		6,000		5,000
Transaction price							$ 7,100
AbbVie
Agreements
Gross proceeds from issuance of private placement	$ 10,000
Collaboration and Stock Purchase Agreement \| AbbVie
Agreements
Additional program initiation period	3 years
Gross proceeds from issuance of private placement				10,000
Development milestone related payment				5,000
Additional development milestone achieved				6,000
Upfront payment				57,000
Upfront payment, cash				42,000
Maximum additional contingent payments receivable				2,100,000
Maximum additional contingent payments receivable, Fees				305,000
Maximum additional contingent payments receivable, Milestones				1,800,000
Fair market value of common stock issued (in dollars)							2,900
Premium of common stock issued (in dollars)							7,100
Transaction price							$ 42,000
Revenue		12,700	$ 4,800	5,600	$ 20,700
Deferred revenue		19,281		19,281		$ 34,007
Collaboration and Stock Purchase Agreement \| AbbVie \| Maximum
Agreements
Number of programs \| Program							4
Number of additional programs \| Program							2
Initial Option Program, Material right for counterparty's right to substitute initial target with backup target \| AbbVie
Agreements
Transaction price							$ 500
Initial Option Program, Right to receive additional services \| AbbVie
Agreements
Transaction price							1,100
Initial Option Program, Material right to receive an exclusive license \| AbbVie
Agreements
Transaction price							8,200
Initial Option Program Performance Obligation \| AbbVie
Agreements
Transaction price							6,900
Collaboration Program Performance Obligation \| AbbVie
Agreements
Transaction price							32,400
Collaboration Agreement \| AbbVie
Agreements
Transaction price							$ 49,100
Deferred revenue		19,300		19,300
Deferred revenue, current portion		$ 9,400		$ 9,400